Clinical Trial Update: A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TEZ/IVA (Lumacaftor/Ivacaftor) in experienced CF subjects has completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-12